SangYun Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6750735/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Creutzfeldt–Jakob disease patient with V180I mutation survived for 16.5Âyears after diagnosis. Acta Neurologica Belgica, 2022, 122, 249-250.	0.5	3
2	Subtle Cognitive Deficits Are Associated with Amyloid-β Positivity, but Not Severity of Self-Reported Decline: Results from the CoSCo Study. Dementia and Geriatric Cognitive Disorders, 2022, 51, 159-167.	0.7	2
3	Survival in Korean Patients with Frontotemporal Dementia Syndrome: Association with Behavioral Features and Parkinsonism. Journal of Clinical Medicine, 2022, 11, 2260.	1.0	Ο
4	Multimer Detection System-Oligomerized Amyloid Beta (MDS-OAβ): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia. International Journal of Alzheimer's Disease, 2022, 2022, 1-6.	1.1	3
5	Predictive Scale for Amyloid PET Positivity Based on Clinical and MRI Variables in Patients with Amnestic Mild Cognitive Impairment. Journal of Clinical Medicine, 2022, 11, 3433.	1.0	3

6 Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer's Disease Patients in Asia. Journal of

#	Article	IF	CITATIONS
19	Association between statin use and Alzheimer's disease with dose response relationship. Scientific Reports, 2021, 11, 15280.	1.6	16
20	Power Spectral Changes of Quantitative EEG in the Subjective Cognitive Decline: Comparison of Community Normal Control Groups. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2783-2790.	1.0	9
21	Increased telomere length in patients with frontotemporal dementia syndrome. Journal of the Neurological Sciences, 2021, 428, 117565.	0.3	7
22	Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial. Dementia and Geriatric Cognitive Disorders, 2021, 50, 289-295.	0.7	0
23	A Pathogenic Presenilin-1 Val96Phe Mutation from a Malaysian Family. Brain Sciences, 2021, 11, 1328.	1.1	2
24	Dysregulated expression levels of APH1B in peripheral blood are associated with brain atrophy and amyloid-β deposition in Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 183.	3.0	13
25	A missense variant in SHARPIN mediates Alzheimer's disease-specific brain damages. Translational Psychiatry, 2021, 11, 590.	2.4	10
26	Presence of endogenous Aβ in plasma of patient with Alzheimer's disease differentiates Aβ oligomerization tendencies caused by synthetic Aβ. Alzheimer's and Dementia, 2021, 17, .	0.4	3
27	Subthreshold amyloid pathology and changes in functional brain networks in patients with delayed cognitive decline after stroke. Alzheimer's and Dementia, 2021, 17, .	0.4	0
28	CSF total tau∫l±â€synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylation. Alzheimer's and Dementia, 2021, 17, .	0.4	0
29	Idiopathic normal pressure hydrocephalus with synucleinopathy: Diagnosis and treatment. Alzheimer's and Dementia, 2021, 17, .	0.4	0
30	Digital Trail Making Testâ€8lack & White: Normal vs MCI. Alzheimer's and Dementia, 2021, 17, .	0.4	0
31	APOE ε4 predicts amyloid PET positive in amnesic subjective cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	Ο
32	Predictability of polygenic risk score for progression to dementia and its interaction with <i>APOE</i> $\hat{l}\mu4$ in mild cognitive impairment. Alzheimer's and Dementia, 2021, 17, .	0.4	0
33	Self―and informantâ€reported cognitive functioning and awareness in subjective cognitive decline, mild cognitive impairment, and very mild Alzheimer disease. International Journal of Geriatric Psychiatry, 2020, 35, 91-98.	1.3	24
34	CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylation. Alzheimer's Research and Therapy, 2020, 12, 83.	3.0	14
35	Hypersensitivity to atypical antipsychotics in dementia with Lewy bodies: is it common or rare?. Parkinsonism and Related Disorders, 2020, 76, 44-45.	1.1	1
36	Tackling challenges in care of Alzheimer's disease and other dementias amid the COVIDâ€19 pandemic, now and in the future. Alzheimer's and Dementia, 2020, 16, 1571-1581.	0.4	122

#	Article	IF	CITATIONS
37	Digital Trail Making Testâ€Black and White: For android and iOS. Alzheimer's and Dementia, 2020, 16, e037886.	0.4	Ο
38	Whole exome sequencing analysis identifies genes and pathways in sporadic earlyâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037899.	0.4	0
39	Neuropsychological factors related to progression of subjective cognitive decline. Alzheimer's and Dementia, 2020, 16, e041628.	0.4	0
40	Association of Apolipoprotein E genetic variation in Alzheimer's disease in a Korean population. Alzheimer's and Dementia, 2020, 16, e041859.	0.4	0
41	QEEG: The tentative biomarker for early screening of preclinical Alzheimer's disease or progressiveness of subjective cognitive decline. Alzheimer's and Dementia, 2020, 16, e042834.	0.4	2
42	Posterior cortical atrophy syndrome: Asian study. Alzheimer's and Dementia, 2020, 16, e044452.	0.4	1
43	Alzheimer's disease risk factor mutations in patients diagnosed with Creutzfeltâ€Jakob disease. Alzheimer's and Dementia, 2020, 16, e045035.	0.4	0
44	Plasma amyloidâ€Î² oligomerization assay as a screening test for abnormal amyloid status. Alzheimer's and Dementia, 2020, 16, e045754.	0.4	0
45	Amyloid Metabolism and Amyloid-Targeting Blood-Based Biomarkers of Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 75, 685-696.	1.2	9
46	Dynamic association between AT(N) profile and cognition mediated by cortical thickness in Alzheimer's continuum. NeuroImage: Clinical, 2020, 27, 102282.	1.4	2
47	Predictors of pre-operative cognitive impairment in meningioma patients over 60 years old. BMC Neurology, 2020, 20, 225.	0.8	4
48	Pathogenic PSEN1 Glu184Gly Mutation in a Family from Thailand with Probable Autosomal Dominant Early Onset Alzheimer's Disease. Diagnostics, 2020, 10, 135.	1.3	3
49	Pathogenic PSEN1 Thr119lle Mutation in Two Korean Patients with Early-Onset Alzheimer's Disease. Diagnostics, 2020, 10, 405.	1.3	2
50	Blood Amyloid-β Oligomerization as a Biomarker of Alzheimer's Disease: A Blinded Validation Study. Journal of Alzheimer's Disease, 2020, 75, 493-499.	1.2	35
51	Clinical Aspects of Neurobehavioral Symptoms of Dementia. Dementia and Neurocognitive Disorders, 2020, 19, 54.	0.4	5
52	Coping with Dementia in the Middle of the COVID-19 Pandemic. Journal of Korean Medical Science, 2020, 35, e383.	1.1	40
53	Reliability and Validity of a Short Form of the Korean Dementia Screening Questionnaire-Cognition.		

#	Article	IF	CITATIONS
55	Autosomal Dominant Frontotemporal Lobar Degeneration in a Filipino Family with Progranulin Mutation. Dementia and Geriatric Cognitive Disorders, 2020, 49, 557-564.	0.7	2
56	A Comprehensive Visual Rating Scale for Predicting Progression from Mild Cognitive Impairment to Dementia in Patients with Alzheimer's Pathology or Suspected Non-Alzheimer's Pathology. Dementia and Neurocognitive Disorders, 2020, 19, 129.	0.4	2
57	APOE Promoter Polymorphism-219T/G is an Effect Modifier of the Influence of APOE ε4 on Alzheimer's Disease Risk in a Multiracial Sample. Journal of Clinical Medicine, 2019, 8, 1236.	1.0	40
58	<p>Early-onset Alzheimer's disease patient with prion (PRNP) p.Val180Ile mutation</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2003-2013.	1.0	16
59	Current fluid biomarkers, animal models, and imaging tools for diagnosing chronic traumatic encephalopathy. Molecular and Cellular Toxicology, 2019, 15, 353-368.	0.8	5
60	Novel amyloid precursor protein mutation, Val669Leu ("Seoul APPâ€), in a Korean patient with early-onset Alzheimer's disease. Neurobiology of Aging, 2019, 84, 236.e1-236.e7.	1.5	10
61	Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 89.	3.0	41
62	Novel prion mutation (p.Tyr225Cys) in a Korean patient with atypical Creutzfeldt–Jakob disease. Clinical Interventions in Aging, 2019, Volume 14, 1387-1397.	1.3	6
63	APP, PSEN1, and PSEN2 Mutations in Asian Patients with Early-Onset Alzheimer Disease. International Journal of Molecular Sciences, 2019, 20, 4757.	1.8	38
64	The usefulness of visual rating of posterior atrophy in predicting rapid cognitive decline in Alzheimer disease: A preliminary study. International Journal of Geriatric Psychiatry, 2019, 34, 625-632.	1.3	3
65	Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer's disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial. Alzheimer's Research and Therapy, 2019, 11, 37.	3.0	14
66	Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 40.	3.0	38
67	Analysis of 50 Neurodegenerative Genes in Clinically Diagnosed Early-Onset Alzheimer's Disease. International Journal of Molecular Sciences, 2019, 20, 1514.	1.8	57
68	Can the trail making test black and white predict white matter hyperintensity on MRI?. Journal of Clinical Neuroscience, 2019, 64, 155-159.	0.8	3
69	PLâ€02â€02: ALZHEIMER'S DISEASE BLOODâ€BASED BIOMARKERS AND AD CONTROL. Alzheimer's and Dementi 2019, 15, P530.	a ₇ 0.4	0
70	A Comparative Evaluation of the KDSQ-C, AD8, and SMCQ as a Cognitive Screening Test to Be Used in National Medical Check-ups in Korea. Journal of Korean Medical Science, 2019, 34, e111.	1.1	16

71

#	Article	IF	CITATIONS
73	Clinical genetic strategies for early onset neurodegenerative diseases. Molecular and Cellular Toxicology, 2018, 14, 123-142.	0.8	20
74	Cyproterone acetate as a treatment for moderateâ€toâ€severe inappropriate sexual behavior in dementia. Geriatrics and Gerontology International, 2018, 18, 366-368.	0.7	4
75	Decreased Metabolism in the Posterior Medial Network with Concomitantly Increased Metabolism in the Anterior Temporal Network During Transient Global Amnesia. Brain Topography, 2018, 31, 468-476.	0.8	5
76	Functional dissection of astrocyte-secreted proteins: Implications in brain health and diseases. Progress in Neurobiology, 2018, 162, 37-69.	2.8	111
77	P1â€165: A NOVEL APP VAL604MET MUTATION IN A THAI WITH EARLYâ€ONSET ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P341.	⁵ 0.4	0
78	P3â€099: A KNOWN PSEN1 E184G MUTATION IN AN EOAD PATIENT FROM THAILAND. Alzheimer's and Dementia, 2018, 14, P1105.	0.4	0
79	P2â€109: A KNOWN PSEN1 MUTATION, T116I, ASSOCIATED WITH EARLY ONSET ALZHEIMER'S DISEASE IN A KOREAN FAMILY. Alzheimer's and Dementia, 2018, 14, P711.	0.4	0
80	P1â€166: SCREENING FOR MUTATIONS IN EARLYâ€ONSET ALZHEIMER'S DISEASE FROM THAILAND WITH ADAM GENEPANEL 1. Alzheimer's and Dementia, 2018, 14, P342.	0.4	0
81	Hydrocephalus in a Patient with Alzheimer's Disease. Dementia and Neurocognitive Disorders, 2018, 17, 32.	0.4	6
82	P2â€296: PREâ€EXISTING BILATERAL ANTERIOR CINGULATE ATROPHY IN PATIENTS WITH TRANSIENT GLOBAL AMNESIA. Alzheimer's and Dementia, 2018, 14, P795.	0.4	0
83	P2â€330: RARE V180I MUTATION IN PRNP GENE OF A KOREAN PATIENT WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P809.	0.4	0
84	P1â€⊋57: A BLOOD TEST OF AMYLOIDOPATHY FOR DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P379.	0.4	0
85	P1â€033: A MULTICENTER, RANDOMIZED, OPENâ€LABEL, PROSPECTIVE TRIAL TO EVALUATE THE SAFETY OF DONEPEZIL HYDROCHLORIDE 23 MG WITH OR WITHOUT INTERMEDIATE DOSE TITRATION IN PATIENTS WITH ALZHEIMER'S DISEASE TAKING DONEPEZIL HYDROCHLORIDE 10 MG: ODESA STUDY. Alzheimer's and Dementia. 2018, 14, P279.	0.4	0
86	P4â€069: BLOODâ€BASED DIAGNOSIS OF ALZHEIMER'S DISEASE USING PHOTOOXIDATIONâ€INDUCED FLUORESCENCE AMPLIFICATION (PIFA) OF AMYLOID Î ² FROM NEURONAL EXOSOMES. Alzheimer's and Dementia, 2018, 14, P1459.	0.4	0
87	Artificial Neural Network: Understanding the Basic Concepts without Mathematics. Dementia and Neurocognitive Disorders, 2018, 17, 83.	0.4	62
88	P1â€337: GERSTMANN‧TRAUSSLER‧CHEINKER DISEASE DUE TO A DE NOVO PRION PROTEIN GENE MUTATI Alzheimer's and Dementia, 2018, 14, P422.	ON. 0.4	0
89	Gut Microbiota and Their Neuroinflammatory Implications in Alzheimer's Disease. Nutrients, 2018, 10, 1765.	1.7	161
90	Detection of cognitive impairment using a machine-learning algorithm. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2939-2945.	1.0	18

#	Article	IF	CITATIONS
91	P4â€039: <i>APP</i> , <i>PSEN1</i> , AND <i>PSEN2</i> MUTATIONS IN EARLYâ€ONSET ALZHEIMER'S DISEASE DISCOVERED IN ASIAN COUNTRIES: A GENETIC SCREENING STUDY OF FAMILIAL AND SPORADIC CASES. Alzheimer's and Dementia, 2018, 14, P1447.	0.4	0
92	Early Onset Alzheimer's Disease Presenting as Logopenic Primary Progressive Aphasia. Dementia and Neurocognitive Disorders, 2018, 17, 66.	0.4	3
93	Driving Cessation and Cognitive Dysfunction in Patients with Mild Cognitive Impairment. Journal of Clinical Medicine, 2018, 7, 545.	1.0	14
94	Plasma Oligomeric Beta Amyloid in Alzheimer's Disease with History of Agent Orange Exposure. Dementia and Neurocognitive Disorders, 2018, 17, 41.	0.4	10
95	Identification of a novel mutation in APP gene in a Thai subject with early-onset Alzheimer's disease. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 3015-3023.	1.0	15

96 Multimodal Assessment of Neural Substrates in Computerized Cognitive Training: A Preliminary Study.

#	Article	IF	CITATIONS
109	[P3–029]: CYPROTERONE ACETATE TO TREAT MODERATE TO SEVERE INAPPROPRIATE SEXUAL BEHAVIOR IN DEMENTIA. Alzheimer's and Dementia, 2017, 13, P941.	0.4	1
110	[P3–250]: AMYLOID BETA OLIGOMERIZATION IN PLASMA AS A POTENTIAL BLOODâ€BASED BIOMARKER FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1038.	0.4	0
111	Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region. Dementia and Geriatric Cognitive Disorders Extra, 2017, 6, 382-395.	0.6	9
112	A Methodological Perspective on the Longitudinal Cognitive Change after Stroke. Dementia and Geriatric Cognitive Disorders, 2017, 44, 311-319.	0.7	9
113	[P2–465]: COMPARISON BETWEEN THE MINIâ€MENTAL STATE EXAMINATION AND THE MINIâ€MENTAL STATE EXAMINATIONâ€2 IN KOREAN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P818.	0.4	0
114	[P3–086]: NOVEL AND KNOWN RARE SORL1 MUTATIONS IN KOREAN AD PATIENTS. Alzheimer's and Dementia, 2017, 13, P965.	0.4	0
115	[P1–152]: A NOVEL APP (V669L) MUTATION IN A KOREAN AD PATIENT. Alzheimer's and Dementia, 2017, 13, P301.	0.4	0
116	[P1–255]: EFFECT OF ADMISSION BLOOD PRESSURE VARIABILITY OF ACUTE STROKE ON LONGITUDINAL POST‧TROKE COGNITIVE CHANGES. Alzheimer's and Dementia, 2017, 13, P345.	0.4	2
117	[P1–312]: EFFECT OF COCHLEAR IMPLANTATION ON COGNITIVE FUNCTION: A PRELIMINARY STUDY USING NONVERBAL COMMUNICATION. Alzheimer's and Dementia, 2017, 13, P373.	0.4	0
118	[P2–112]: A NOVEL PSEN1 G417A MUTATION IN A KOREAN AD PATIENT WITH PARKINSONISM. Alzheimer's and Dementia, 2017, 13, P649.	0.4	0
119	[P2–216]: SEASONAL VARIATION IN THE INCIDENCE OF TRANSIENT GLOBAL AMNESIA IN SOUTH KOREA. Alzheimer's and Dementia, 2017, 13, P693.	0.4	0
120	Apolipoprotein ε7 allele in memory complaints: insights through protein structure prediction. Clinical Interventions in Aging, 2017, Volume 12, 1095-1102.	1.3	10
121	Nonmotor Symptoms of Parkinson's Disease. Parkinson's Disease, 2017, 2017, 1-2.	0.6	12
122	Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial. PLoS ONE, 2017, 12, e0182123.	1.1	10
123	Characteristic differences in the mini-mental state examination used in Asian countries. BMC Neurology, 2017, 17, 141.	0.8	30
124	Supernumerary phantom limb in a patient with basal ganglia hemorrhage - a case report and review of the literature. BMC Neurology, 2017, 17, 180.	0.8	4
125	Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42. Alzheimer's Research and Therapy, 2017, 9, 86.	3.0	57
126	Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 98.	3.0	108

SangYun Kim

#	Article	lF	CITATIONS
127	Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment. Alzheimer's Research and Therapy, 2017, 9, 99.	3.0	11
128	A case of possibly pathogenic PSEN2 R62C mutation in a patient with probable early-onset Alzheimer's dementia supported by structure prediction. Clinical Interventions in Aging, 2017, Volume 12, 367-375.	1.3	3
120	Seasonal Variation in the Incidence of Transient Global Amnesia in South Korea. Journal of Clinical		

#	Article	IF	CITATIONS
145	P3â€⊋27: Differential Involvement of Corticohippocampal Circuits During Transient Global Amnesia. Alzheimer's and Dementia, 2016, 12, P912.	0.4	Ο
146	P4-050: Two Novel GRN Mutations in Korean Patients Diagnosed with Early Onset Alzheimer's Disease. , 2016, 12, P1033-P1033.		0
147	P4-219: The Diffuse, Not Focal, Frontal Atrophy Subtype Shows Worse Prognosis in Frontotemporal Dementia. , 2016, 12, P1111-P1112.		0
148	P1â€⊋41: Transient Global Amnesia Impairs Smallâ€World Topology. Alzheimer's and Dementia, 2016, 12, P499.	0.4	0
149	Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. Journal of Alzheimer's Disease, 2016, 52, 1403-1413.	1.2	17
150	In silico modeling of pathogenic point mutations in PSEN1 as studied in South-east Asia. Toxicology and Environmental Health Sciences, 2016, 8, 135-153.	1.1	2
151	P1â€208: a Novel Mutation in the <i>S100A9</i> Gene Associated with Alzheimer's Disease in a Malaysian Family: Five Cases Report. Alzheimer's and Dementia, 2016, 12, P485.	0.4	0
152	Increased CSF tau level is correlated with decreased lamina cribrosa thickness. Alzheimer's Research and Therapy, 2016, 8, 6.	3.0	13
153	Disruption of the Posterior Medial Network during the Acute Stage of Transient Global Amnesia. Clinical EEG and Neuroscience, 2016, 47, 69-74.	0.9	11
154	A Comparison of Five Types of Trail Making Test in Korean Elderly. Dementia and Neurocognitive Disorders, 2016, 15, 135.	0.4	7
155	Neurosyphilis Mimicking Creutzfeldt-Jakob Disease. Dementia and Neurocognitive Disorders, 2016, 15, 170.	0.4	1
156	Genomic Characteristics of Genetic Creutzfeldt-Jakob Disease Patients with V180I Mutation and Associations with Other Neurodegenerative Disorders. PLoS ONE, 2016, 11, e0157540.	1.1	7
157	Estimation of the size of the iatrogenic Creutzfeldt-Jakob disease outbreak associated with cadaveric dura mater grafts in Korea. Epidemiology and Health, 2016, 38, e2016059.	0.8	1
158	P3-015: Novel PSEN1 mutation (E280K) in a malaysian family. , 2015, 11, P625-P625.		0
159	P4-217: Novel Al ² specific recombinant monoclonal antibodies with high sensitivity. , 2015, 11, P863-P863.		0
160	P2-018: Novel, probably pathogenic PSEN1 mutation (G209A) in a korean Alzheimer's disease patient. , 2015, 11, P488-P488.		0
161	P4-077: Cognitive trajectory and MR biomarkers in post-stroke cognitive impairment patients. , 2015, 11, P800-P800.		1
162	A Comprehensive Visual Rating Scale of Brain Magnetic Resonance Imaging: Application in Elderly Subjects with Alzheimer's Disease, Mild Cognitive Impairment, and Normal Cognition. Journal of Alzheimer's Disease, 2015, 44, 1023-1034.	1.2	19

CANAVAN	12
SangYun	КІМ
Shirorun	I CI IVI

#	Article	IF	CITATIONS
163	Magnetic microparticle-based multimer detection system for the detection of prion oligomers in sheep. International Journal of Nanomedicine, 2015, 10, 241.	3.3	12

164 Utility of Oblique Coronal Images in Elderly and Cognitively Impaired Patients. Journal of Clinical

#	Article	IF	CITATIONS
181	Alternative Type of the Trail Making Test in Nonnative English-Speakers: The Trail Making Test-Black & White. PLoS ONE, 2014, 9, e89078.	1.1	31
182	P1-377: EFFICACY AND TOLERABILITY OF DONEPEZIL 23-MG/DAY VERSUS DONEPEZIL 10-M/DAY IN KOREAN PATIENTS WITH MODERATE TO SEVERE AD: STUDY 326 SUBANALYSIS. , 2014, 10, P452-P453.		0
183	P3-181: FUNCTIONAL RECOVERY IN ACUTE STROKE IS INFLUENCED BY SPECIFIC DOMAINS OF COGNITIVE FUNCTION. , 2014, 10, P694-P695.		Ο
184	Diagnostic methods and biomarkers for Alzheimer's disease. Toxicology and Environmental Health Sciences, 2014, 6, 133-147.	1.1	12
185	Characterization of inflammatory biomarkers and candidates for diagnosis of Alzheimer's disease. Biochip Journal, 2014, 8, 155-162.	2.5	12
186	Clinical and genetic analysis of MAPT, GRN, and C9orf72 genes in Korean patients with frontotemporal dementia. Neurobiology of Aging, 2014, 35, 1213.e13.1213.e17.	1.5	35
187	Left dominance of EEG abnormalities in patients with transient global amnesia. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 825-829.	0.9	14
188	Clinical Experience of Modified Diffusionâ€Weighted Imaging Protocol for Lesion Detection in Transient Global Amnesia: An 8â€Year Largeâ€Scale Clinical Study. Journal of Neuroimaging, 2014, 24, 331-337.	1.0	29
189	Probable novel PSEN2 Val214Leu mutation in Alzheimer's disease supported by structural prediction. BMC Neurology, 2014, 14, 105.	0.8	24
190	The Heterogeneity and Natural History of Mild Cognitive Impairment of Visual Memory Predominant Type. Journal of Alzheimer's Disease, 2014, 43, 143-152.	1.2	12
191	P1-185: ALTERATION OF CORTICAL NEURONAL ACTIVITY DURING THE ACUTE STAGE OF TRANSIENT GLOBAL AMNESIA. , 2014, 10, P367-P367.		Ο
192	P3-228: A COMPREHENSIVE VISUAL RATING SCALE ON BRAIN MRI: APPLICATION TO ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE MEMORY IMPAIRMENT. , 2014, 10, P714-P714.		0
193	P1-132: PATHOGENIC PSEN1 MUTATION DETECTED IN A KOREAN EOAD PATIENT. , 2014, 10, P348-P348.		0
194	P2-170: CLINICAL STAGE OF SPORADIC CREUTZFELDT-JAKOB DISEASE. , 2014, 10, P532-P533.		1
195	IC-P-035: CORRELATION BETWEEN CSF BIOMARKERS AND QUANTIFIED PIB BURDEN IN ALZHEIMER'S DISEASE PATIENTS. , 2014, 10, P21-P22.		Ο
196	P1-133: POSSIBLY PATHOGENIC PSEN2 (R62C) MUTATION IN A KOREAN AD PATIENT. , 2014, 10, P348-P349.		0
197	Word Definition Ability in Patients with Alzheimer's disease. Dementia and Neurocognitive Disorders, 2014, 13, 7.	0.4	4
198	Driving in Patients with Dementia: A CREDOS (Clinical Research Center for Dementia of South Korea) Study. Dementia and Neurocognitive Disorders, 2014, 13, 83.	0.4	4

#	Article	IF	CITATIONS
199	Differential White Matter Connectivity in Early Mild Cognitive Impairment According to CSF Biomarkers. PLoS ONE, 2014, 9, e91400.	1.1	12
200	The genetics of Alzheimer's disease. Clinical Interventions in Aging, 2014, 9, 535.	1.3	131
201	The Survey for the Effect of Guideline about Activities of Daily Living in Dementia Patients "Il-sang-ye-chan" Campaign. Dementia and Neurocognitive Disorders, 2014, 13, 101.	0.4	2
202	Genetic factors in frontotemporal dementia: A review. Toxicology and Environmental Health Sciences, 2013, 5, 113-130.	1.1	2
203	Parietal variant Alzheimer's disease presenting with dyscalculia. Neurological Sciences, 2013, 34, 779-780.	0.9	5
204	Neurologists' Awareness and Preparedness on Prion Diseases in Korea. Dementia and Neurocognitive Disorders, 2013, 12, 9.	0.4	3
205	Reflections of Two Parallel Pathways between the Hippocampus and Neocortex in Transient Global Amnesia: A Cross-Sectional Study Using DWI and SPECT. PLoS ONE, 2013, 8, e67447.	1.1	13
206	A novel PSEN1 H163P mutation in a patient with early-onset Alzheimer's disease: Clinical, neuroimaging, and neuropathological findings. Neuroscience Letters, 2012, 530, 109-114.	1.0	20
207	Comparison between the Story Recall Test and the Word-List Learning Test in Korean patients with mild cognitive impairment and early stage of Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 396-404.	0.8	35
208	A voxel-based morphometric study of cortical gray matter volume changes in Alzheimer's disease with white matter hyperintensities. Journal of Clinical Neuroscience, 2012, 19, 1506-1510.	0.8	18
209	Lesion detectability on diffusion-weighted imaging in transient global amnesia: the influence of imaging timing and magnetic field strength. Neuroradiology, 2012, 54, 329-334.	1.1	38
210	Neurologic signs in relation to cognitive function in subcortical ischemic vascular dementia: a CREDOS (Clinical Research Center for Dementia of South Korea) study. Neurological Sciences, 2012, 33, 839-846.	0.9	20
211	Voxel-based morphometric study of brain volume changes in patients with Alzheimer's disease assessed according to the Clinical Dementia Rating score. Journal of Clinical Neuroscience, 2011, 18, 916-921.	0.8	22
212	Clinical practice guideline for dementia by Clinical Research Center for Dementia of South Korea. Journal of the Korean Medical Association, 2011, 54, 861.	0.1	26
213	Validation Analysis of the Attention Questionnaire Scale. Journal of Alzheimer's Disease, 2011, 24, 393-402.	1.2	9
214	Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: A preliminary report. Geriatrics and Gerontology International, 2011, 11, 90-97.	0.7	4
215	Diffusion-weighted imaging and magnetic resonance spectroscopy of sporadic Creutzfeldt–Jakob disease: correlation with clinical course. Neuroradiology, 2011, 53, 939-945.	1.1	33
216	The usefulness of the story recall test in patients with mild cognitive impairment and Alzheimer's disease. Aging, Neuropsychology, and Cognition, 2011, 18, 214-229.	0.7	29

#	Article	IF	CITATIONS
217	Cerebellar Hypoperfusion during Transient Global Amnesia: An MRI and Oculographic Study. Journal		